Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GLP1R | P43220 | 8/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25924806 | 0.89 | MEN1 (0.46) | KMT2AMEN1GLP1RLMNASMN1; SMN2 | |
| SCHEMBL24765414 | 0.88 | MEN1 (0.51) | KMT2AMEN1GLP1RSMN1; SMN2HPGD | |
| SCHEMBL25885537 | 0.87 | MEN1 (0.50) | KMT2AMEN1GLP1RSMN1; SMN2GAA | |
| SCHEMBL21105906 | 0.87 | KMT2A (0.53) | KMT2AMEN1GLP1RLMNASMN1; SMN2 | |
| SCHEMBL22837784 | 0.87 | KMT2A (0.53) | KMT2AMEN1GLP1RLMNASMN1; SMN2 | |
| SCHEMBL23945413 | 0.87 | MEN1 (0.44) | KMT2AMEN1GLP1RGAA | |
| SCHEMBL17853874 | 0.84 | KMT2A (0.66) | KMT2AMEN1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL25729276 | 0.84 | KMT2A (0.50) | KMT2AMEN1GLP1RLMNASMN1; SMN2 | |
| SCHEMBL25703715 | 0.84 | KMT2A (0.45) | KMT2AMEN1GLP1RLMNASMN1; SMN2 | |
| SCHEMBL23696502 | 0.83 | MEN1 (0.46) | KMT2AMEN1GLP1RGAAUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | KMT2A 1096/4885MEN1 1064/4885GLP1R 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.